Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

A Canadian teen's breasts grew fourfold after receiving the Pfizer COVID-19 vaccine, raising concerns about a rare condition ...

Royalty Pharma said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages the healthcare firm's operations, as it seeks to simplify its corporate structure.